TriangleCD19/CD22-CAR-transduced T cells (NCT05442515)
CD19/CD22-CAR-transduced T cells trial for B-Non Hodgkin Lymphoma (NCT05442515). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Acute lymphoblastic leukemia is the most common childhood cancer, and nine in ten are cured. When it comes back, the odds fall below half.
CAR T cells aimed at a marker called CD19 rescued many of those children. But leukemia learns: some cells drop CD19 and slip away. Cells aimed at a second marker, CD22, get dodged the same way.
The idea: one T cell that watches both doors at once.
A child's own T cells receive one gene that builds both receptors. The National Cancer Institute's earlier two-target design was safe, but the cells faded quickly. This version is rebuilt to last.
Sara Silbert leads it at the NIH Clinical Center, for ages three to thirty-nine. Safety first. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.